NeoPharm CO. LTD (KQ:092730) — Stock Price
NeoPharm CO. LTD (KQ:092730) is currently trading at ₩24100.00 KRW, up 13.95% today. Over the past 52 weeks, shares have ranged between ₩15760.00 and ₩24100.00. This page tracks NeoPharm CO. LTD's live share price on the KQ exchange, its daily price and volume history, and — where reported — its income statement, balance sheet, cash flow statement, and earnings history. For company valuation and market capitalisation context, see NeoPharm CO. LTD (092730) total market value.
NeoPharm CO. LTD (092730) Stock Price Chart — Daily History & Trading Volume
The chart below tracks NeoPharm CO. LTD's daily closing share price and trading volume on the KQ exchange over the past year, giving a clear view of recent price momentum and liquidity.
NeoPharm CO. LTD Income Statement — Revenue, Profit & Earnings by Year
NeoPharm CO. LTD's annual income statement shows how revenue converts into profit each fiscal year, including gross profit, operating income, EBITDA, and net income.
| Fiscal Year | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Total Revenue | ₩119.01 Billion | ₩97.10 Billion | ₩85.03 Billion | ₩87.93 Billion | ₩81.63 Billion |
| Cost of Revenue | ₩44.99 Billion | ₩31.72 Billion | ₩26.65 Billion | ₩25.54 Billion | ₩22.98 Billion |
| Gross Profit | ₩74.03 Billion | ₩65.39 Billion | ₩58.38 Billion | ₩62.39 Billion | ₩58.64 Billion |
| Research & Development | ₩3.41 Billion | ₩2.65 Billion | ₩2.85 Billion | ₩2.94 Billion | ₩2.80 Billion |
| SG&A | ₩44.26 Billion | ₩36.28 Billion | ₩32.98 Billion | ₩36.02 Billion | ₩32.99 Billion |
| Total Operating Expenses | ₩94.36 Billion | ₩71.80 Billion | ₩63.59 Billion | ₩65.50 Billion | ₩59.72 Billion |
| Operating Income | ₩24.65 Billion | ₩25.29 Billion | ₩21.43 Billion | ₩22.42 Billion | ₩21.90 Billion |
| EBITDA | — | — | — | — | — |
| EBIT | — | — | — | ₩22.43 Billion | ₩21.90 Billion |
| Interest Expense | ₩40.78 Million | ₩21.32 Million | ₩8.84 Million | ₩38.46 Million | ₩56.37 Million |
| Income Before Tax | ₩30.21 Billion | ₩29.37 Billion | ₩23.32 Billion | ₩23.84 Billion | ₩22.94 Billion |
| Income Tax Expense | — | — | — | ₩6.12 Billion | ₩4.81 Billion |
| Net Income | ₩23.06 Billion | ₩23.21 Billion | ₩17.03 Billion | ₩17.71 Billion | ₩18.13 Billion |
NeoPharm CO. LTD Balance Sheet — Assets, Liabilities & Shareholder Equity
The balance sheet below summarizes NeoPharm CO. LTD's financial position at each fiscal year-end — what it owns (assets), what it owes (liabilities), and the resulting shareholder equity.
| Fiscal Year | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Total Assets | ₩192.44 Billion | ₩177.46 Billion | ₩155.35 Billion | ₩143.41 Billion | ₩132.98 Billion |
| Total Current Assets | ₩153.05 Billion | ₩134.50 Billion | ₩131.27 Billion | ₩121.48 Billion | ₩113.55 Billion |
| Cash & Equivalents | — | — | ₩10.88 Billion | ₩7.05 Billion | ₩11.19 Billion |
| Short-term Investments | ₩108.29 Billion | ₩100.11 Billion | ₩102.60 Billion | ₩98.00 Billion | ₩84.99 Billion |
| Net Receivables | ₩10.85 Billion | ₩8.56 Billion | ₩6.54 Billion | ₩7.51 Billion | ₩8.32 Billion |
| Inventory | ₩12.68 Billion | ₩10.20 Billion | ₩8.75 Billion | ₩7.97 Billion | ₩8.09 Billion |
| Property, Plant & Equipment | — | — | ₩9.34 Billion | ₩9.74 Billion | ₩10.12 Billion |
| Goodwill | — | — | — | — | — |
| Total Liabilities | ₩15.56 Billion | ₩17.43 Billion | ₩13.14 Billion | ₩13.10 Billion | ₩15.26 Billion |
| Total Current Liabilities | ₩15.13 Billion | ₩16.94 Billion | ₩13.14 Billion | ₩12.94 Billion | ₩14.88 Billion |
| Long-term Debt | — | — | ₩0.00 | ₩0.00 | ₩0.00 |
| Net Debt | — | — | — | — | — |
| Total Stockholder Equity | ₩176.88 Billion | ₩160.03 Billion | ₩142.21 Billion | ₩130.30 Billion | ₩117.72 Billion |
| Retained Earnings | ₩130.57 Billion | ₩113.60 Billion | ₩96.11 Billion | ₩83.85 Billion | ₩71.10 Billion |
NeoPharm CO. LTD Cash Flow Statement — Operating, Investing & Financing Activities
This cash flow statement breaks down how NeoPharm CO. LTD generates and spends cash across operating, investing, and financing activities each fiscal year, including free cash flow and capital expenditures.
| Fiscal Year | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Operating Cash Flow | ₩18.63 Billion | ₩23.26 Billion | ₩18.16 Billion | ₩21.68 Billion | ₩17.07 Billion |
| Capital Expenditures | ₩3.08 Billion | ₩20.83 Billion | ₩806.43 Million | ₩320.11 Million | ₩285.62 Million |
| Free Cash Flow | ₩15.55 Billion | ₩2.43 Billion | ₩17.35 Billion | ₩21.20 Billion | ₩16.34 Billion |
| Investing Cash Flow | ₩-6.22 Billion | ₩-16.35 Billion | ₩-8.80 Billion | ₩-16.69 Billion | ₩-4.74 Billion |
| Financing Cash Flow | ₩-6.50 Billion | ₩-5.92 Billion | ₩-5.75 Billion | ₩-9.52 Billion | ₩-6.57 Billion |
| Dividends Paid | ₩5.87 Billion | ₩5.47 Billion | ₩5.47 Billion | ₩5.08 Billion | ₩5.87 Billion |
| Stock-Based Compensation | — | — | — | — | — |
| Depreciation | ₩2.54 Billion | ₩1.67 Billion | ₩1.09 Billion | ₩1.50 Billion | ₩1.49 Billion |
| Change in Cash | ₩6.35 Billion | ₩998.06 Million | ₩3.83 Billion | ₩-4.14 Billion | ₩5.67 Billion |
NeoPharm CO. LTD Earnings History — EPS Actual vs. Analyst Estimates
Track NeoPharm CO. LTD's quarterly earnings per share (EPS) against Wall Street estimates, along with the earnings surprise percentage for each reporting period.
| Report Date | EPS Actual | EPS Estimate | Surprise |
|---|---|---|---|
| May 07, 2026 | — | — | — |
| Nov 11, 2025 | 438.54 | — | — |
| Aug 11, 2025 | 451.81 | — | — |
| May 09, 2025 | 456.28 | — | — |
| Mar 17, 2025 | 430.56 | — | — |
| Nov 08, 2024 | 277.20 | — | — |
| Aug 09, 2024 | 752.18 | — | — |
| May 10, 2024 | 509.00 | 466.00 | +9.23% |